GlassScriptPhysician profile
John M Gentry
NPI 1932351061
$2,715.74
in general payments reported to CMS, 2019-2025
24 companies · $571 in 2025
The $571 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $611 · 2023: $845 · 2024: $273 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $749.00 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $329.11 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $274.92 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $200.31 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $191.06 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $151.74 | 2021-2025 | Trintellix |
| Lundbeck LLC | $100.38 | 2023-2025 | Rexulti |
| Alkermes, INC. | $99.60 | 2021-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $83.55 | 2021-2025 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $72.67 | 2023-2025 | Subvenite, Lamotrigine |
| Masimo Corporation | $63.92 | 2023 | Emma and Isa |
| Janssen Pharmaceuticals, INC | $62.26 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Corium, LLC | $48.15 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $44.35 | 2022-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $38.63 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $36.96 | 2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $35.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.65 | 2024 | Cobenfy |
| Neos Therapeutics, LP | $21.81 | 2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $21.45 | 2023 | Xelstrym |
| Indivior INC. | $19.50 | 2025 | Sublocade |
| Braeburn INC. | $16.13 | 2025 | Brixadi |
| Collegium Pharmaceutical, INC. | $13.65 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $13.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.